Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

van de Donk, Niels ^{[2
,3
]}

Delforge, Michel ^{[4
]}

Einsele, Hermann ^{[5
]}

De Stefano, Valerio ^{[6
]}

Lindsey-Hill, Joanne ^{[7
]}

Vincent, Laure ^{[8
]}

Kirkpatrick, Suriya ^{[9
]}

Besemer, Britta ^{[10
]}

Gonzalez Garcia, Maria Esther ^{[11
]}

Karlin, Lionel ^{[12
]}

Ghilotti, Francesca ^{[13
]}

Diels, Joris ^{[14
]}

Morano, Raul ^{[15
]}

Albrecht, Claire ^{[16
]}

Strulev, Vadim ^{[14
]}

Haddad, Imene ^{[16
]}

Pei, Lixia ^{[17
]}

Kobos, Rachel ^{[17
]}

Smit, Jennifer ^{[18
]}

Slavcev, Mary ^{[19
]}

Marshall, Alexander ^{[17
]}

Weisel, Katja ^{[20
]}

Moreau, Philippe ^{[21
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[2] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[3] Canc Ctr Amsterdam, Amsterdam, Netherlands

[4] Univ Leuven, Leuven, Belgium

[5] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[6] Catholic Univ, Fdn Policlin A Gemelli, IRCCS, Rome, Italy

[7] Nottinghamshire Univ Hosp NHS Trust, Nottingham, England

[8] CHU Montpellier, Montpellier, France

[9] Univ West England, Bristol, Avon, England

[10] Univ Hosp Tubingen, Tubingen, Germany

[11] Univ Hosp Cabuenes, Gijon, Spain

[12] Ctr Hosp Lyon Sud, Pierre Benite, France

[13] Janssen Cilag SpA, Cologno Monzese, Italy

[14] Janssen Pharmaceut NV, Beerse, Belgium

[15] Janssen Cilag, Madrid, Spain

[16] Janssen Cilag, Issy Les Moulineaux, France

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Spring House, PA USA

[19] Janssen Global Serv, Raritan, NJ USA

[20] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[21] Univ Hosp Hotel Dieu, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-294

引用

页码：S199 / S199

页数：1

共 50 条

[31] Real-world treatment patterns and clinical outcomes in patients with triple-class exposed relapsed or refractory multiple myeloma in United States clinical practice
Chari, Ajai
Nair, Sandhya
Lin, Xiwu
Marshall, Alexander
Slavcev, Mary
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S165 - S166
[32] CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
Cavo, Michele
HAEMATOLOGICA, 2023, 108 (08) : 1988 - 1990
[33] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
Dima, Danai
Davis, James A.
Ahmed, Nausheen
Jia, Xuefei
Sannareddy, Aishwarya
Shaikh, Hira
Shune, Leyla
Kaur, Gurbakhash
Khouri, Jack
Afrough, Aimaz
Strouse, Christopher
Lochner, Jonathan
Mahmoudjafari, Zahra
Raza, Shahzad
Valent, Jason
Anderson Jr, Larry D.
Anwer, Faiz
Abdallah, Al-Ola
Hashmi, Hamza
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
[34] Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States
Ma, Qiufei
Song, Xue
Delea, Thomas E.
Kroog, Glenn S.
Ge, Wenzhen
Chi, Lei
Moynahan, Aaron
Weycker, Derek
Lorenc, Karen Rodriguez
BLOOD, 2022, 140 : 5298 - 5300
[35] Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan
Iida, Shinsuke
Nakakoji, Mayuko
Spanopoulos, Dionysis
Okazuka, Kiyoshi
Parulekar, Vipul
Ishida, Tadao
FUTURE ONCOLOGY, 2022, 18 (34) : 3839 - 3852
[36] COST-EFFECTIVENESS OF TALQUETAMAB-TGVS VS IDECABTAGENE VICLEUCEL FOR TRIPLE-CLASS EXPOSED RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Rong, R.
Tang, T.
Shi, L.
VALUE IN HEALTH, 2024, 27 (06) : S10 - S10
[37] Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data
Sinyavskaya, Liliya
Meche, Aster
Faucher, Ariane
Hlavacek, Patrick
Johnson, Sarasa M. A.
DiBonaventura, Marco
Vekeman, Francis
Ren, Jinma
Schepart, Alex
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (05) : 789 - 801
[38] From triple-class exposed (TCE) to penta-exposed and triple-class refractory (PE-TCR): Real-world outcomes across a spectrum of advanced relapsed or refractory multiple myeloma (RRMM) patients (Pts) in the United States.
Delea, Thomas E.
Song, Xue
Ge, Wenzhen
Chi, Lei
Eichten, Caitlin
Moynahan, Aaron
Weycker, Derek
Ma, Qiufei
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] REAL-WORLD ECONOMIC BURDEN AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE UNITED STATES
Chari, A.
Lin, X.
Ammann, E.
Matt, K.
Potluri, R.
Nair, S.
VALUE IN HEALTH, 2023, 26 (12) : S180 - S180
[40] Real-World Costs, Health Care Resource Utilization (HCRU), and Outcomes Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US
Nair, S.
Lin, X.
Potluri, R.
Slavcev, M.
Marshall, A.
VALUE IN HEALTH, 2022, 25 (12) : S152 - S152

← 1 2 3 4 5 →